Here are five points:
1. The global market is anticipated to grow at a compound annual growth rate of 5.4 percent through 2022.
2. An increasing demand for minimally invasive surgery as well as a growing aging population will drive the market.
3. The cost-effectiveness of bone stimulation devices as opposed to alternative options for bone fracture treatments will also spur market growth.
4. The spinal fusion market segment captured the largest market share in 2016, due to the proven safety and efficacy of spinal stimulators and high volume of spine cases.
5. Key market companies include Altis Biologics, Arthrex, Bioventus, DJO Finance, DePuy Synthes, Ember Therapeutics, Harvest Technologies, ITO Co., Isto Biologics, Medtronic, Orthofix International, Regen Lab, Stryker and Zimmer Biomet.
More articles on devices:
Device executive pleads guilty to stealing company secrets and plans — 5 key details
Mazor Q1 revenue jumps 83% with 12 Mazor X orders: 6 key notes
Conventus Orthopaedics raises $20M to fund Cage repair therapy — 4 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
